LLY

962.69

-1.73%↓

JNJ

221.49

-0.61%↓

ABBV

200.33

-2.6%↓

UNH

373.71

+1.54%↑

AZN

182.39

-0.45%↓

LLY

962.69

-1.73%↓

JNJ

221.49

-0.61%↓

ABBV

200.33

-2.6%↓

UNH

373.71

+1.54%↑

AZN

182.39

-0.45%↓

LLY

962.69

-1.73%↓

JNJ

221.49

-0.61%↓

ABBV

200.33

-2.6%↓

UNH

373.71

+1.54%↑

AZN

182.39

-0.45%↓

LLY

962.69

-1.73%↓

JNJ

221.49

-0.61%↓

ABBV

200.33

-2.6%↓

UNH

373.71

+1.54%↑

AZN

182.39

-0.45%↓

LLY

962.69

-1.73%↓

JNJ

221.49

-0.61%↓

ABBV

200.33

-2.6%↓

UNH

373.71

+1.54%↑

AZN

182.39

-0.45%↓

Начало・Списък с акции・Pulse Biosciences Inc

Pulse Biosciences Inc

Затворен

СекторЗдравеопазване

19.55 1.45

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

18.95

Максимум

19.86

Ключови измерители
By Trading Economics
Приходи	2M -17M
Продажби	137K 401K
EPS	-0.18
Марж на печалбата	-6,603.409
Служители	116
EBITDA	-1.4M -19M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+53.14% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-173M 1.4B
Предишно отваряне	18.1
Предишно затваряне	19.55

Настроения в новините

By Acuity

100%

333 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

16.59 / 17.17 Подкрепа & съпротива

Pulse Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.05.2026 г., 23:58 ч. UTC

Печалби

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7.05.2026 г., 22:57 ч. UTC

Печалби

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7.05.2026 г., 23:52 ч. UTC

Печалби

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7.05.2026 г., 23:28 ч. UTC

Пазарно говорене

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7.05.2026 г., 23:11 ч. UTC

Печалби

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7.05.2026 г., 23:06 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7.05.2026 г., 23:05 ч. UTC

Печалби

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7.05.2026 г., 23:04 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7.05.2026 г., 23:03 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7.05.2026 г., 23:03 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7.05.2026 г., 23:02 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7.05.2026 г., 23:00 ч. UTC

Пазарно говорене

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7.05.2026 г., 22:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.05.2026 г., 22:45 ч. UTC

Пазарно говорене

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7.05.2026 г., 22:42 ч. UTC

Печалби

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7.05.2026 г., 22:33 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7.05.2026 г., 22:32 ч. UTC

Печалби

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7.05.2026 г., 22:31 ч. UTC

Печалби

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7.05.2026 г., 22:31 ч. UTC

Печалби

Macquarie: 68% of FY Income From International >MQG.AU

7.05.2026 г., 22:30 ч. UTC

Печалби

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7.05.2026 г., 22:30 ч. UTC

Печалби

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7.05.2026 г., 22:29 ч. UTC

Печалби

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7.05.2026 г., 22:28 ч. UTC

Печалби

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7.05.2026 г., 22:28 ч. UTC

Печалби

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7.05.2026 г., 22:27 ч. UTC

Печалби

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7.05.2026 г., 22:27 ч. UTC

Печалби

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7.05.2026 г., 22:26 ч. UTC

Печалби

Macquarie to End Share Buyback Extended in November>MQG.AU

7.05.2026 г., 22:25 ч. UTC

Печалби

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Сравнение с други в отрасъла

Ценова промяна

Pulse Biosciences Inc Прогноза

Ценова цел

By TipRanks

53.14% нагоре

12-месечна прогноза

Среден 30 USD 53.14%

Висок 30 USD

Нисък 30 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Pulse Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Pulse Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.59 / 17.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Настроение

By Acuity

333 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.